The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
14-Jul-23
$333 million
Target:
Canopy Growth Corporation
Acquiror:
N/A
Advised Canopy Growth, a leading diversified cannabis company, on a series of agreements, including privately negotiated redemption agreements with certain holders of its unsecured senior notes due July 15, 2023 and agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021, that will have the overall effect of deleveraging the Company’s balance sheet by ~C$437mm over time
14-Jul-23
$674 million
Target:
Juice Plus+
Advised Juice Plus+, a global health and wellness company in the direct selling space on a comprehensive recapitalization transaction
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
25-Oct-22
Pending
Undisclosed
Target:
Acreage Holdings
Acquiror:
Canopy Growth Corporation
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
13-Oct-22
$47 million
Target:
Electro Optic Systems
Acquiror:
Washington H. Soul Pattinson
Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson
09-Sep-21
$2.1 billion
Target:
easyJet plc
Acquiror:
N/A
Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF
18-Mar-21
$750 million
Target:
Canopy Growth Corporation
Acquiror:
King Street Capital Management, L.P.
Advised Canopy Growth, a leading diversified cannabis company, on its US$750 million term loan financing with King Street Capital Management, L.P.
11-Mar-21
$2.1 billion
Target:
Education Australia’s 40% Stake in IDP Education
Acquiror:
Education Australia’s 38 University Shareholders
Advising ASX-listed IDP Education on the restructure of Education Australia’s 40% ownership stake in the business
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
01-Feb-21
$292 million
Target:
Sunwing Airlines and Sunwing Vacations
Acquiror:
Canada Enterprise Emergency Funding Corp.
Advised Sunwing, a leading Canadian travel company and leisure airline, on its C$375mm financing under the Large Employer Emergency Financing Facility (LEEFF) program administered by the Canada Enterprise Emergency Funding Corp. and overseen by the Government of Canada
23-Nov-20
$120 million
Target:
Greencore Group plc
Acquiror:
N/A
Advised Greencore Group plc, a leading UK manufacturer of convenience foods based in Ireland, on its £90mm non pre-emptive equity placing
01-Oct-20
$2.6 billion
Target:
Rolls-Royce £2bn Fully Underwritten Rights Issue
Acquiror:
N/A
Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package
29-Sep-20
$200 million
Target:
Travel & Transport
Acquiror:
Corporate Travel Management
Advising Corporate Travel Management on its acquisition of US-based travel management company Travel & Transport and the associated A$375mm equity raise
11-Jun-20
$760 million
Target:
CSM Bakery Solutions
Acquiror:
Rhône Group
Advised the Ad-Hoc Group of First Lien and Second Lien Lenders on consensual out-of-court amend & extend
06-Apr-20
$352 million
Target:
WH Smith PLC
Acquiror:
N/A
Advised WH Smith PLC, one of the UK’s leading retailers, on its £166m non pre-emptive equity placing and new £120mm financing facility
27-Nov-19
$320 million
Target:
David’s Bridal Inc.
Acquiror:
N/A
Advised David’s Bridal, a leading bridal gown and special occasion dress retailer, on its out-of-court recapitalization
18-Nov-18
$876 million
Target:
David's Bridal
Acquiror:
N/A
Advised the Ad Hoc Group of the company's $481mm term loan with respect to the company's prepackaged Chapter 11 restructuring
10-Jul-18
$1.1 billion
Target:
The AA plc
Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities
23-May-18
$93 million
Target:
Dairy Crest Group PLC
Advised Dairy Crest, a leading British dairy company, on a non-pre-emptive cash placing, raising proceeds of approximately £70 million
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
30-Mar-15
$950 million
Target:
Quindell plc’s Professional Services Division
Acquiror:
Slater and Gordon
Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings